Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amiodarone-induced hypercholesterolemia is associated with a decrease in liver LDL receptor mRNA

F Hudig1, O Bakker, W M Wiersinga

  • 1Department of Endocrinology, University of Amsterdam, The Netherlands.

FEBS Letters
|March 14, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.

European journal of endocrinology·2021
Same author

Harmonizing light transmission aggregometry in the Netherlands by implementation of the SSC-ISTH guideline.

Platelets·2020
Same author

Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.

Journal of endocrinological investigation·2020
Same author

Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.

Journal of endocrinological investigation·2018
Same author

Thyroid disease symptoms during early pregnancy do not identify women with thyroid hypofunction that should be treated.

Clinical endocrinology·2017
Same author

Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.

Orphanet journal of rare diseases·2017

Amiodarone increases cholesterol by reducing LDL receptor mRNA in rat livers, similar to hypothyroidism effects. This suggests a key mechanism for amiodarone-induced hypercholesterolemia.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Endocrinology

Background:

  • Amiodarone alters thyroid hormone levels (triiodothyronine) and increases plasma cholesterol.
  • These changes mimic those observed in hypothyroidism.
  • The precise mechanism of amiodarone-induced hypercholesterolemia requires elucidation.

Purpose of the Study:

  • To investigate the mechanism behind amiodarone-induced hypercholesterolemia.
  • To examine the gene expression of key cholesterol metabolism proteins in rat livers.
  • To compare amiodarone's effects with those of induced hypothyroidism.

Main Methods:

  • Rats were treated with amiodarone or propylthiouracil (hypothyroidism model).
  • Gene expression of cholesterol 7 alpha-hydroxylase, LDL receptor, and HMG-CoA reductase was analyzed in liver tissue.

Related Experiment Videos

  • mRNA levels were quantified after 14 days of treatment.

    • Main Results:

    • Amiodarone treatment led to a significant downregulation (approx. 50%) of LDL receptor mRNA.
    • Hypothyroid animals (propylthiouracil-treated) also showed decreased LDL receptor mRNA levels.
    • Gene expression of cholesterol 7 alpha-hydroxylase and HMG-CoA reductase remained unchanged in both treatment groups.

    Conclusions:

    • Amiodarone-induced hypercholesterolemia is associated with reduced levels of LDL receptor mRNA in the liver.
    • The downregulation of LDL receptors may contribute to elevated plasma cholesterol levels.
    • This finding provides insight into the molecular mechanisms linking amiodarone use to lipid profile changes.